STEAP1 CAR-T cells + collagen-binding interleukin-12

STEAP1 CAR-T cells + collagen-binding interleukin-12 is an experimental armored chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This immunotherapy consists of autologous T cells engineered to target the six-transmembrane epithelial antigen of the prostate 1 (STEAP1), which is highly expressed in over 85% of mCRPC cases. To overcome the immunosuppressive tumor microenvironment and the systemic toxicity typically associated with interleukin-12 (IL-12), these CAR-T cells are further engineered to conditionally secrete a fusion protein comprising IL-12 and a collagen-binding domain (CBD) upon antigen engagement. The CBD is designed to anchor the potent IL-12 cytokine to the collagen-rich tumor stroma, thereby localizing its immune-activating effects—such as the recruitment of NK cells and cross-presenting dendritic cells—within the tumor while minimizing systemic exposure and off-target toxicities like hepatotoxicity.

Other names

CBD-IL-12-armored STEAP1 CAR-T cellsCBD-IL12-armored STEAP1 CAR-T cellsCBD-IL 12-armored STEAP1 CAR-T cellsSTEAP1-directed CAR-T cells engineered to conditionally secrete a collagen-binding domain-IL-12 fusion proteinSTEAP-1-directed CAR-T cells engineered to conditionally secrete a collagen-binding domain-IL-12 fusion proteinSTEAP 1-directed CAR-T cells engineered to conditionally secrete a collagen-binding domain-IL-12 fusion proteinSTEAP1 CAR-T-CBD-IL12STEAP-1 CAR-T-CBD-IL12STEAP 1 CAR-T-CBD-IL12